脑脊液PDGFRβ与衰老、血脑屏障损伤、神经炎症及阿尔茨海默病病理改变的相关性
研究在瑞典BioFINDER-2队列771名认知未受损、轻度认知障碍和痴呆参与者中检测脑脊液PDGFRβ,分析其与衰老、血脑屏障损伤、神经炎症及AD病理标志物的关联。结果显示脑脊液PDGFRβ与年龄、神经炎症标志物(YKL-40、GFAP)及血脑屏障通透性(QAlb)升高相关,但与Aβ-PET、tau-PET、APOE ε4、脑萎缩及白质病变无关。
要点
- 脑脊液PDGFRβ升高与年龄、YKL-40、GFAP及QAlb升高相关。
- PDGFRβ与Aβ-PET、tau-PET、APOE ε4、脑萎缩及白质病变无关联。
- PDGFRβ可能参与年龄相关血脑屏障破坏及神经炎症。
核心结论
- 脑脊液PDGFRβ反映的周细胞损伤可能与年龄相关血脑屏障破坏及神经炎症有关,但与阿尔茨海默病相关病理改变无关。
研究设计与样本
- 研究纳入瑞典BioFINDER-2队列771名参与者,其中认知未受损408名、轻度认知障碍175名、痴呆188名。
- 检测脑脊液PDGFRβ,并与Aβ-PET、tau-PET、APOE ε4基因型、MRI皮层厚度、白质病变及脑血流量进行关联分析。
- 分析脑脊液PDGFRβ在衰老、血脑屏障功能障碍(以脑脊液/血浆白蛋白比值QAlb衡量)与神经炎症(脑脊液YKL-40和GFAP水平)关系中的作用。
主要发现
- 队列平均年龄67岁(认知未受损62.8岁,轻度认知障碍69.9岁,痴呆70.4岁),男性占50.1%(认知未受损46.6%,轻度认知障碍53.7%,痴呆54.3%)。
- 较高的脑脊液PDGFRβ浓度与较高年龄相关(b=19.1,β=0.5,95%CI 16-22.2,p<0.001)。
- 较高的脑脊液PDGFRβ浓度与脑脊液神经炎症标志物YKL-40升高相关(b=3.4,β=0.5,95%CI 2.8-3.9,p<0.001),与GFAP升高相关(b=27.4,β=0.4,95%CI 20.9-33.9,p<0.001),与QAlb升高相关(b=37.4,β=0.2,95%CI 24.9-49.9,p<0.001)。
- 年龄也与较差的血脑屏障完整性相关,该关联部分由PDGFRβ和神经炎症标志物介导(占总效应的16%-33%)。
- PDGFRβ与APOE ε4基因型、Aβ和tau病理的PET成像、脑萎缩及白质病变的MRI测量均无关联(p>0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Injured pericytes in the neurovascular unit release platelet-derived growth factor β (PDGFRβ) into the CSF. However, it is not clear how pericyte injury contributes to Alzheimer disease (AD)-related changes and blood-brain barrier (BBB) damage. We aimed to test whether CSF PDGFRβ was associated with different AD-associated and age-associated pathologic changes leading to dementia. METHODS: PDGFRβ was measured in the CSF of 771 participants with cognitively unimpaired (CU, n = 408), mild cognitive impairment (MCI, n = 175), and dementia (n = 188) from the Swedish BioFINDER-2 cohort. We then checked association with β-amyloid (Aβ)-PET and tau-PET standardized uptake value ratio, APOE ε4 genotype and MRI measurements of cortical thickness, white matter lesions (WMLs), and cerebral blood flow. We also analyzed the role of CSF PDGFRβ in the relationship between aging, BBB dysfunction (measured by CSF/plasma albumin ratio, QAlb), and neuroinflammation (i.e., CSF levels of YKL-40 and glial fibrillary acidic protein [GFAP], preferentially expressed in reactive astrocytes). RESULTS: The cohort had a mean age of 67 years (CU = 62.8, MCI = 69.9, dementia = 70.4), and 50.1% were male (CU = 46.6%, MCI = 53.7%, dementia = 54.3%). Higher CSF PDGFRβ concentrations were related to higher age (b = 19.1, β = 0.5, 95% CI 16-22.2, p < 0.001), increased CSF neuroinflammatory markers of glial activation YKL-40 (b = 3.4, β = 0.5, 95% CI 2.8-3.9, p < 0.001), GFAP (b = 27.4, β = 0.4, 95% CI 20.9-33.9, p < 0.001), and worse BBB integrity measured by QAlb (b = 37.4, β = 0.2, 95% CI 24.9-49.9, p < 0.001). Age was also associated with worse BBB integrity, and this was partly mediated by PDGFRβ and neuroinflammatory markers (16%-33% of total effect). However, PDGFRβ showed no associations with APOE ε4 genotype, PET imaging of Aβ and tau pathology, or MRI measures of brain atrophy and WMLs (p > 0.05). DISCUSSION: In summary, pericyte damage, reflected by CSF PDGFRβ, may be involved in age-related BBB disruption together with neuroinflammation, but is not related to Alzheimer-related pathologic changes.
引用
- Cicognola C, Mattsson-Carlgren N, van Westen D, et al. Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes. Neurology. 2023. PMID: 37137722. doi:10.1212/WNL.0000000000207358
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。